Targretin Related Published Studies
Well-designed clinical trials related to Targretin (Bexarotene)
Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I. [2008.04.10]
Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. [2008.04.10]
Phase II clinical trial of bexarotene gel 1% in psoriasis. [2007.05]
Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies. [2006.10.20]
A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB phototherapy for moderate to severe psoriasis vulgaris. [2006.01]
Novel treatment of chronic severe hand dermatitis with bexarotene gel. [2004.03]
Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. [2001.05]
Placebo-controlled trial of bexarotene, a retinoid x receptor agonist, as maintenance therapy for patients treated with chemotherapy for advanced non-small-cell lung cancer. [2001.02]
Well-designed clinical trials possibly related to Targretin (Bexarotene)
Single-dose rexinoid rapidly and specifically suppresses serum thyrotropin in normal subjects. [2007.01]
Single-Dose Rexinoid Rapidly and Specifically Suppresses Serum Thyrotropin in Normal Subjectsa. [2006.10.24]
The treatment of cutaneous T-cell lymphoma with a novel retinoid. [2000.11]
Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids. [1998.08.01]
Other research related to Targretin (Bexarotene)
Clinical and in vitro resistance to bexarotene in adult T-cell leukemia: loss of RXR-alpha receptor. [2008.09.15]
A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia. [2008.09.01]
CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature. [2008.09]
Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate. [2008.05]
The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice. [2008.04.22]
Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes. [2008.04]
Modulation by bexarotene of mRNA expression of genes in mouse lung tumors. [2008.03]
Folliculotropic mycosis fungoides responding to bexarotene gel. [2008.02]
Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial. [2008.01]
A phase I study of docetaxel and bexarotene. [2008]
A phase I study of bexarotene and rosiglitazone in patients with refractory cancers. [2008]
Bexarotene and narrowband ultraviolet B phototherapy combination treatment for mycosis fungoides. [2007.12]
The optimal use of bexarotene in cutaneous T-cell lymphoma. [2007.09]
[Bexarotene therapy in folliculotropic cutaneous T-cell lymphoma] [2007.08]
Bexarotene-induced hypothyroidism: bexarotene stimulates the peripheral metabolism of thyroid hormones. [2007.07]
The optimal use of bexarotene in cutaneous T-cell lymphoma. [2007.06.06]
Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. [2007.05.01]
Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification. [2007.05.01]
Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell lymphoma. [2007.04]
Results of a Phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. [2007.03.15]
A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer. [2007.03.15]
Bexarotene and interferon-alpha combination therapy in a patient affected by relapsing anaplastic large cell lymphoma with cutaneous involvement. [2007.02]
Juvenile mycosis fungoides treated with bexarotene and PUVA. [2007.01]
Evidence of myeloid differentiation in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene. [2007.01]
The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia. [2006.12]
Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. [2006.08]
[Central hypothyroidism associated with bexarotene therapy] [2006.07]
[Treatment of mycosis fungoides with PUVA and bexarotene] [2006.06]
Prevention of mouse lung tumors by targretin. [2006.05.01]
Treatment of mycosis fungoides with denileukin diftitox and oral bexarotene. [2006.05]
Regression of extranodal natural killer/T-cell lymphoma, nasal type with denileukin diftitox (Ontak) and bexarotene (Targretin): report of a case. [2006.05]
Bexarotene in the treatment of cutaneous T-cell lymphoma. [2006.05]
Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma. [2006.04]
Prevention of lung cancer progression by bexarotene in mouse models. [2006.03.02]
A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer. [2006.02.15]
Sezary syndrome associated with granulomatous lesions during treatment with bexarotene. [2006.02]
Bexarotene and erlotinib for aerodigestive tract cancer. [2005.12.01]
[Treatment of cutaneous T-cell lymphomas with bexarotene] [2005.12]
Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancer. [2005.08.20]
Successful treatment of T-cell post-transplant lymphoproliferative disorder with the retinoid analog bexarotene. [2005.08]
A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. [2005.07.15]
Lack of apoptosis of Sezary cells in the circulation following oral bexarotene therapy. [2005.06]
Bexarotene treatment of late-stage mycosis fungoides and Sezary syndrome: development of extracutaneous lymphoma in 6 patients. [2005.06]
The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma. [2005.05]
Efficacy of Targretin on methylnitrosourea-induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis. [2005.02]
Oral bexarotene in a therapy-resistant Sezary syndrome patient: observations on Sezary cell compartmentalization. [2005.01]
Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene. [2005.01]
A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer. [2004.12.15]
Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series. [2004.10]
Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation, and improves differentiation in lesional skin. [2004.08]
Sustained remission of treatment-resistant cutaneous T-cell lymphoma with oral bexarotene. [2004.06]
Follicular mycosis fungoides: successful treatment with oral bexarotene. [2004.05]
Bexarotene: a clinical review. [2004.04]
Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms. [2004.03]
Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. [2003.11]
Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences. [2003.10]
A multiparameter flow cytometric analysis of the effect of bexarotene on the epidermis of the psoriatic lesion. [2003.09]
Effects of oral bexarotene (targretin) on the minimal erythema dose for broadspectrum UVB light. [2003.07]
Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma. [2003.06]
Bexarotene gel: a new skin-directed treatment option for cutaneous T-cell lymphomas. [2003.04]
Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. [2003.03.15]
Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma. [2003.03]
Long-term control of mycosis fungoides of the hands with topical bexarotene. [2003.03]
Mycosis fungoides with follicular mucinosis displaying aggressive tumor-stage transformation : successful treatment using radiation therapy plus oral bexarotene combination therapy. [2003]
Bexarotene is a new treatment option for lymphomatoid papulosis. [2003]
Optimizing bexarotene therapy for cutaneous T-cell lymphoma. [2002.11]
Treatment of mycosis fungoides with oral bexarotene combined with PUVA. [2002.09]
Response of CD30+ large cell lymphoma of skin to bexarotene. [2002.05]
Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. [2002.03]
Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy. [2001.12]
Oral bexarotene in the treatment of cutaneous T-cell lymphoma. [2001.09]
Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. [2001.05.15]
Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. [2001.05.01]
Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. [2001.05]
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. [2001]
Bexarotene ligand pharmaceuticals. [2000.12]
Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms. [2000.11]
Bexarotene. [2000.07]
A phase II evaluation of bexarotene (Targretin) capsules in patients with metastatic melanoma. [2000.07]
Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. [1998.02.01]
Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. [1996.12.15]
Other possibly related research studies
Nonclassical retinoids and lung carcinogenesis. [2005.01]
Follicular mycosis fungoides: variability of a rare entity. [2005.01]
Mycosis fungoides and the Sezary syndrome. [2004.09]
Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma. [2004.07]
Potential nonhormonal therapeutics for medical treatment of leiomyomas. [2004.05]
Pharmacology of oral chemotherapy agents. [2003.11]
[Standard and experimental therapy of cutaneous T-cell lymphoma] [2003.12]
Management of mycosis fungoides: Part 2. Treatment. [2003.10]
|
